MetaVia (MTVA) Short term Debt (2017 - 2018)
MetaVia's (MTVA) quarterly Short term Debt came in at $9.4 million in Q4 2018, up 596.46% YoY from $1.4 million in Q4 2017, and up 156.37% on a QoQ basis from $3.7 million in Q3 2018.
MetaVia (MTVA) Short term Debt (2017 - 2018) Analysis & Trends
MetaVia (MTVA) has 2 years of Short term Debt data on file, last reported at $9.4 million in Q4 2018.
- Quarterly Short term Debt rose 596.46% year-over-year to $9.4 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $9.4 million (up 596.46% YoY) and the FY2018 annual result came in at $9.4 million, up 596.46% from the prior year.
- Short term Debt rose to $9.4 million in Q4 2018, from $3.7 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $9.4 million in Q4 2018 to a low of $1.4 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 9.44 Mn |
| Sep 30, 2018 | 3.68 Mn |
| Jun 30, 2018 | 2.65 Mn |
| Mar 31, 2018 | 2.36 Mn |
| Dec 31, 2017 | 1.36 Mn |